330600-85-6
3(R)-[1(S)-Acetamido-2-ethylbutyl]-4(R)-guanidino-2(S)-hydroxycyclopentane-1(S)-carboxylic acid
CAS: 229614-55-5;330600-85-6
Molecular Formula: C15H28N4O4
330600-85-6 - Names and Identifiers
330600-85-6 - Physico-chemical Properties
| Molecular Formula | C15H28N4O4 |
| Molar Mass | 328.41 |
| Density | 1.39g/cm3 |
| Refractive Index | 1.613 |
330600-85-6 - Reference Information
| new anti-influenza drug | influenza (hereinafter referred to as "influenza") is a respiratory infectious disease caused by influenza virus infection. The viruses that cause influenza are generally divided into three types, namely Type A (A), Type B (B) and Type C (C). The one that is easy to break out, spread and epidemic in the population is Type A. At present, the effective chemical drugs for the virus are oseltamivir, zanamivir and peramivir, which have just been approved for marketing. The targets of these drugs are mainly neuraminidase against the virus. Paramivir was first developed by the BioCryst of the United States, and was first approved for listing on Japan in January 2010 after the introduction of Shiono Yoshiki Pharmaceutical of Japan. The drug can be used in patients with severe illness, Tamiflu resistance and cannot be taken orally. On April 5, 2013, the State Food and Drug Administration approved the new anti-influenza drug peramivir sodium chloride injection. According to the introduction of the website of the State Food and Drug Administration, peramivir is a new type of anti-influenza virus drug, and existing clinical trial data prove that it is effective against influenza A and B. H7N9 belongs to influenza A virus subtype. Paramivir Sodium Chloride Injection is the first intravenous neuraminidase inhibitor in my country. It is for those patients with severe influenza, patients who cannot receive inhaled or oral neuraminidase inhibitors, and other neuraminidase inhibitors. Patients with poor efficacy or drug resistance provide new treatment options. The State Food and Drug Administration stated that the national drug review department has strictly reviewed the peramivir sodium chloride injection in accordance with the regulations of the new drug review, and adopted early intervention in research and development, and strengthened communication and guidance. Measures to speed up the approval progress to meet clinical needs on the premise of ensuring the safety and effectiveness of drugs. At present, as neuraminidase inhibitors, oseltamivir phosphate tablets and zanamivir inhalants are also approved for marketing in China. China is one of the few countries that have approved the listing of Paramivir, such as the United States, Japan and South Korea. The State Food and Drug Administration did not specifically disclose the pharmaceutical companies approved to produce this time. Guangzhou Nanxin Pharmaceutical Co., Ltd. is currently the only domestic company that produces peramivir sodium chloride injection. |
| Advantages compared with oseltamivir | Paramivir and oseltamivir (trade name "Tamiflu") are both neuraminidase inhibitors, and the antiviral mechanism is the same as oseltamivir, suitable for the treatment of influenza A. The clinical trials carried out by peramivir used oseltamivir as the control drug. The test results showed that there was no significant difference between the efficacy and adverse reactions of oseltamivir. oseltamivir is an oral preparation, which is not convenient for critically ill patients to use, and due to its relatively early marketing time, drug resistance has been found. Paramivir and oseltamivir have different structures and are suitable for the treatment of patients resistant to oseltamivir; in addition, because peramivir is an injection with a long half-life, clinical use also has fast onset and long duration. Features. The approval of peramivir provides new treatment options for patients with severe influenza, patients who cannot receive inhaled or oral drug treatment, and patients who are resistant to oseltamivir. |
Last Update：2024-04-09 19:05:09
Supplier List
Spot supply
Product Name: Peramivir Monomer Visit Supplier Webpage Request for quotationCAS: 330600-85-6
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Spot supply
Product Name: Peramivir Monomer Visit Supplier Webpage Request for quotationCAS: 330600-85-6
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
View History